Advertisement
Advertisement
U.S. Markets close in 4 hrs 45 mins
Advertisement
Advertisement
Advertisement
Advertisement

Immuneering Corporation (IMRX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
25.87+0.02 (+0.08%)
As of 11:15AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close25.85
Open26.11
Bid25.61 x 800
Ask26.00 x 1000
Day's Range25.38 - 27.16
52 Week Range16.06 - 33.99
Volume4,345
Avg. Volume140,606
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est43.67
  • GlobeNewswire

    Immuneering Reports Compelling Preclinical Data on IMM-1-104 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    Preclinical Data Demonstrated Broad Antitumor Activity Across KRAS, NRAS and BRAF Mutant Tumor Models, Established Novel Mechanism of Action for its Dual MEK Inhibition and Showed Synergies with Sotorasib in KRAS-G12C Mutant Pancreatic Cancer Company Hosting Key Opinion Leader Event on October 12, 2021 at 11:30 am Eastern Time CAMBRIDGE, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neurosc

  • GlobeNewswire

    Immuneering to Present Key Preclinical Data Across Several Poster Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    Preclinical Data Demonstrates Broad Antitumor Activity of IMM-1-104 Across RAS and RAF Mutant Tumors and Highlights Mechanistic Aspects of its Dual MEK Inhibition Company to Host Key Opinion Leader Event on October 12, 2021 at 11:30 am Eastern Time CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signalin

  • GlobeNewswire

    Immuneering Announces Inclusion in the Russell 2000® Index

    CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced that Immuneering Corporation has been selected to be added to the Russell 2000® Index effective September 20, 2021, after the close of the U.S. equity markets. “We are pleased to have been selected for inclusion in the R

Advertisement
Advertisement